文献速递乳腺癌

CDK4/6抑制剂联合内分泌治疗对比内分泌单药治疗激素受体阳性HER2阴性晚期乳腺癌:III期随机对照试验重建个体患者数据Meta分析

CDK4/6 inhibitors plus endocrine therapy versus endocrine monotherapy in hormone receptor-positive, HER2-negative advanced breast cancer: a reconstructed individual patient data meta-analysis of phase 3 randomised controlled trials.
PubMed 文献 · Lancet Oncol · 2026-01-01

该重建个体患者数据Meta分析纳入11项III期试验共6035例激素受体阳性HER2阴性晚期乳腺癌患者,评估CDK4/6抑制剂联合内分泌治疗对比内分泌单药的生存获益。结果显示联合治疗在内分泌敏感和内分泌耐药患者中均显著改善无进展生存期和总生存期;各药物均改善无进展生存期,但仅阿贝西利和瑞波西利显示显著总生存期获益,哌柏西利未达统计学显著性,达尔西利数据尚不成熟。

要点

  • CDK4/6抑制剂联合内分泌治疗显著改善HR+/HER2-晚期乳腺癌PFS和OS。
  • 内分泌敏感和耐药患者均从联合治疗中获益。
  • 仅阿贝西利和瑞波西利显示显著OS获益,哌柏西利未达统计学显著性。

核心结论

  • CDK4/6抑制剂联合内分泌治疗显著改善激素受体阳性HER2阴性晚期乳腺癌患者的无进展生存期和总生存期。
  • 无进展生存期和总生存期获益在主要临床亚组中一致。
  • 各药物均改善无进展生存期,但仅瑞波西利和阿贝西利显示统计学显著的总生存期获益,哌柏西利未达统计学显著性,达尔西利数据尚不成熟。

研究设计与样本

  • 重建个体患者数据Meta分析,检索PubMed、Web of Science、Cochrane Library和Scopus(2025年6月2日),纳入III期随机对照试验。
  • 共纳入11项III期试验、6035例患者,涉及阿贝西利、瑞波西利、哌柏西利和达尔西利四种药物。
  • 采用时间-事件算法重建Kaplan-Meier曲线获取个体患者生存数据,使用分层Cox回归模型进行汇总分析,并进行成对随机效应Meta分析。
  • 按内分泌敏感性、年龄、种族、孕激素受体状态、绝经状态、ECOG体能状态、单纯骨病和内脏转移进行分层。
  • 主要结局为无进展生存期和总生存期,方案注册于PROSPERO(CRD420251073444)。

主要发现

  • 按年龄、种族、孕激素受体状态、绝经状态、ECOG体能状态、单纯骨病和内脏转移分层的其他临床相关亚组中,内分泌敏感和内分泌耐药肿瘤患者均显示无进展生存期和总生存期获益。

临床怎么用

  • 对于激素受体阳性HER2阴性晚期乳腺癌,CDK4/6抑制剂联合内分泌治疗应作为标准治疗选择,内分泌敏感和耐药患者均可获益。
  • 选择具体CDK4/6抑制剂时,需考虑总生存期证据差异:阿贝西利和瑞波西利显示显著总生存期获益,哌柏西利未显示显著总生存期获益。
  • 达尔西利的长期生存数据尚不成熟,临床决策需综合考虑。

局限性

  • 需要进一步的头对头比较以及毒性特征和患者报告结局的评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: CDK4/6 inhibitors have shown clinical benefits in patients with hormone receptor-positive, HER2-negative advanced breast cancer. This meta-analysis aims to evaluate their effect on survival outcomes across clinically relevant subgroups. METHODS: For this reconstructed individual patient-level meta-analysis, we searched PubMed, Web of Science, the Cochrane Library, and Scopus on June 2, 2025, for phase 3 trials that compared CDK4/6 inhibitors plus endocrine therapy with endocrine monotherapy in patients with hormone receptor-positive, HER2-negative advanced breast cancer. Kaplan-Meier curves were reconstructed with the use of a time-to-event algorithm to retrieve survival data for individual patients. A series of pooled analyses for the reconstructed individual patient data were conducted with the use of a stratified Cox regression model. A pairwise random-effects meta-analysis was also conducted. Patients were stratified by endocrine sensitivity into endocrine-sensitive and endocrine-resistant, as well as by age, ethnicity, progesterone receptor status, menopausal status, Eastern Cooperative Oncology Group performance status, bone-only disease, and visceral metastasis. Primary outcomes analysed were progression-free survival and overall survival. The protocol is registered in PROSPERO (CRD420251073444). FINDINGS: 11 phase 3 trials, including 6035 patients and four agents-abemaciclib, ribociclib, palbociclib, and dalpiciclib-were included. CDK4/6 inhibitors plus endocrine therapy significantly improved progression-free survival in both endocrine-sensitive (HR 0·57, 95% CI 0·52-0·63; p<0·0001) and endocrine-resistant cancers (0·51, 0·45-0·57; p<0·0001). Overall survival was also improved with CDK4/6 inhibitors plus endocrine therapy in both subgroups: endocrine-sensitive (0·83; 0·74-0·92; p=0·0005) and endocrine-resistant (0·77; 0·67-0·89; p=0·0003). All individual agents, when combined with endocrine therapy showed progression-free survival benefits: abemaciclib (HR 0·53, 95% CI 0·46-0·61; p<0·0001), ribociclib (0·60, 0·52-0·68; p<0·0001), palbociclib (0·56, 0·49-0·65; p<0·0001), and dalpiciclib (0·49, 0·40-0·61; p<0·0001). However, only abemaciclib (0·79, 0·67-0·92; p=0·0031) and ribociclib (0·73, 0·64-0·84; p<0·0001) showed significant overall survival benefits; palbociclib did not reach statistical significance (0·89, 0·77-1·02; p=0·0920), and data for dalpiciclib remain immature. Other clinically relevant subgroups, stratified by age, ethnicity, progesterone receptor status, menopausal status, Eastern Cooperative Oncology Group performance status, bone-only disease, and visceral metastasis, showed progression-free survival and overall survival benefits in patients with endocrine-sensitive and endocrine-resistant tumours. INTERPRETATION: CDK4/6 inhibitors plus endocrine therapy significantly improved survival in hormone receptor-positive, HER2-negative advanced breast cancer. Benefits in progression-free survival and overall survival were consistent across major clinical subgroups. Although all agents improved progression-free survival, only ribociclib and abemaciclib showed statistically significant overall survival benefits, whereas palbociclib did not, and data for dalpiciclib remain immature. Further head-to-head comparisons and assessments of toxicity profiles, as well as patient-reported outcomes, are needed. FUNDING: None.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Beshr MS, Fahaid A, Shembesh RH, et al. CDK4/6 inhibitors plus endocrine therapy versus endocrine monotherapy in hormone receptor-positive, HER2-negative advanced breast cancer: a reconstructed individual patient data meta-analysis of phase 3 randomised controlled trials. Lancet Oncol. 2026. PMID: 42061371. doi:10.1016/S1470-2045(26)00053-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。